Patients’ Perspectives on Residual Symptoms in Bipolar Disorder: A Focus Group Study.

Related Articles
Patients’ Perspectives on Residual Symptoms in Bipolar Disorder: A Focus Group Study.
J Nerv Ment Dis. 2014 Jun 11;
Authors: Samalin L, Bellivier F, Giordana B, Yon L, Milhiet V, El-Hage W, Courtet…

read more

Monitoring pharmacotherapy response, safety, and tolerability to enhance adherence in bipolar disorder.

Related Articles
Monitoring pharmacotherapy response, safety, and tolerability to enhance adherence in bipolar disorder.
J Clin Psychiatry. 2014 May;75(5):e12
Authors: Keck PE
Abstract
Among patients…

read more

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.

Related Articles

Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study.

Br J Psychiatry. 2014 Jun 12;

Authors: Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, Baker RA, Eramo A, McQuade RD, Carson WH, Walling D, Kane JM

Abstract
BACKGROUND: Long-acting injectable formulations of antipsychotics are treatment alternatives to oral agents.
AIMS: To assess the efficacy of aripiprazole once-monthly compared with oral aripiprazole for maintenance treatment of schizophrenia.
METHOD: A 38-week, double-blind, active-controlled, non-inferiority study; randomisation (2:2:1) to aripiprazole once-monthly 400 mg, oral aripiprazole (10-30 mg/day) or aripiprazole once-monthly 50 mg (a dose below the therapeutic threshold for assay sensitivity). (Trial registration: clinicaltrials.gov, NCT00706654.) RESULTS: A total of 1118 patients were screened, and 662 responders to oral aripiprazole were randomised. Kaplan-Meier estimated impending relapse rates at week 26 were 7.12% for aripiprazole once-monthly 400 mg and 7.76% for oral aripiprazole. This difference (-0.64%, 95% CI -5.26 to 3.99) excluded the predefined non-inferiority margin of 11.5%. Treatments were superior to aripiprazole once-monthly 50 mg (21.80%, P⩽0.001).
CONCLUSIONS: Aripiprazole once-monthly 400 mg was non-inferior to oral aripiprazole, and the reduction in Kaplan-Meier estimated impending relapse rate at week 26 was statistically significant v. aripiprazole once-monthly 50 mg.

PMID: 24925984 [PubMed – as supplied by publisher]

read more

Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.

Related Articles
Correlates of subjective well-being in schizophrenic patients treated with atypical antipsychotics.
Int J Psychiatry Clin Pract. 2005;9(2):94-8
Authors: Schimmelmann BG, Moritz S, Karow A, Schafer I…

read more

Sertindole: a clinical efficacy profile.

Related Articles
Sertindole: a clinical efficacy profile.
Int J Psychiatry Clin Pract. 2002;6(1):21-6
Authors: Hale A
Abstract
Sertindole is an effective atypical antipsychotic drug that is associate…

read more

Eight-year follow-up of olanzapine therapy in a previous treatment-refractory schizophrenic patient: a case report.

Related Articles
Eight-year follow-up of olanzapine therapy in a previous treatment-refractory schizophrenic patient: a case report.
Int J Psychiatry Clin Pract. 2002;6(4):211-4
Authors: Sirota P, Benhatov R

read more

Partial compliance with antipsychotics and its impact on patient outcomes.

Related Articles
Partial compliance with antipsychotics and its impact on patient outcomes.
Int J Psychiatry Clin Pract. 2007;11(2):102-11
Authors: Narasimhan M, Un Pae C, Masand N, Masand P
Abstract

read more

Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study.

Related Articles
Antipsychotic drug use pattern for patients with schizophrenia in an outpatient clinic in Turkey: A retrospective study.
Int J Psychiatry Clin Pract. 2004;8(1):41-5
Authors: Yildiz M, Cerit C

read more

Pilot of group intervention for bipolar disorder.

Related Articles
Pilot of group intervention for bipolar disorder.
Int J Psychiatry Clin Pract. 2007;11(4):279-84
Authors: Castle D, Berk M, Berk L, Lauder S, Chamberlain J, Gilbert M
Abstract
Object…

read more

Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable.

Related Articles

Symptom control, functioning and satisfaction among Swiss patients treated with risperidone long-acting injectable.

Int J Psychiatry Clin Pract. 2006;10(3):174-81

Authors: Nick B, Vauth R, Braendle D, Riecher-Rössler A, The Swiss StoRMi Investigators Group

Abstract
Objective: To investigate antipsychotic efficacy and tolerability of risperidone long-acting injectable (RLAI) in Swiss patients with schizophrenia or other psychotic disorders, changed directly from their previous antipsychotic medication. Methods: Patients symptomatically stable for ≥1 month on their previous medication and considered to require a treatment change, received 25 mg RLAI (increased to 37.5 or 50 mg, if required) every 2 weeks for 6 months. Results: Of 60 patients enrolled (68.3% male, average age 40.4 years), most (81.7%) had DSM-IV schizophrenia (mainly paranoid). Previous treatments were with atypical antipsychotics (58.3% of patients), depot (38.3%) and conventional oral (13.3%) neuroleptics. Mean total PANSS scores were significantly reduced from baseline to treatment endpoint (76.1 vs. 64.4, P<0.001), as were all PANSS subscale and symptom factor scores. The CGI, GAF, and patient satisfaction with treatment were also significantly improved at endpoint (P<0.001). At endpoint, 37.0% of patients rated their satisfaction as “very good” compared with only 4.3% at baseline. Mean scores for total ESRS and Parkinsonism subscales were significantly reduced at endpoint (P<0.001). Conclusion: Treatment with RLAI significantly improved disease symptoms, functioning, patient satisfaction, and reduced movement disorders. It provides an important option for long-term treatment of patients with psychotic disorders.

PMID: 24941055 [PubMed]

read more
Page 160 of 162« First...130140150«158159160161162»